信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) 2024-03-19 08:00
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting 2024-03-12 08:00
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 2024-03-07 11:53
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer 2024-03-05 13:35
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia 2024-03-01 08:00
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA 2024-02-20 08:22
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China 2024-02-07 16:35
Innovent Announces Retirement of CFO and Appointment of New CFO 2024-02-05 16:45
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA 2024-01-09 08:00
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity 2024-01-02 08:00
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China 2023-12-28 08:00
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension 2023-12-27 08:00
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation 2023-12-19 08:00
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications 2023-12-18 08:00
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication 2023-12-13 12:56
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study 2023-12-07 09:00
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma 2023-12-06 08:16
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023 2023-12-01 12:00
Innovent's MSCI ESG Rating Upgraded to A 2023-11-30 21:37
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351 2023-11-24 08:42
1 4 5 6 7 8 20